A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

Several new weight loss drugs are undergoing trials in the UK. These drugs will work similarly to those already available but ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

The trial included over 13,000 people across 30 countries and ran for more than 4.5 years, making it the largest and longest study on tirzepatide so far, the company said ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

Investing.com-- Australian shares of Resmed (NYSE: RMD) Inc DRC (ASX: RMD) hit a record high on Friday after the medical ...

Health and Human Services Secretary Robert F. Kennedy Jr. and agency leaders have attributed a panoply of chronic diseases ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...